FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments.
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-saving mode that will result in layoffs for 75% of its U.S. employees.
FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab.
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer, expected Q3 of 2024. Initiation of phase 2 monotherapy dose optimizati...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.